Conditional approval for Sunrise Technologies:
This article was originally published in Clinica
Executive Summary
The FDA has given Sunrise Technologies conditional approval to treat both of a patient's eyes on the same day using its laser vision correction system during clinical studies. The company had originally received FDA approval to treat the second eye after a six-month rest period following the first treatment. The FDA has asked Sunrise to make a minor change to the study protocol. The move follows requests from surgeons and patients wanting to have immediate treatment for the second eye after receiving initial treatment.